Detailed answers about ADK CLINICAL DEVELOPMENT CONSULTANCY LTD, including incorporation, status, business activity, and accounts information.
When was ADK CLINICAL DEVELOPMENT CONSULTANCY LTD founded?
ADK CLINICAL DEVELOPMENT CONSULTANCY LTD was officially incorporated on 29 January 2026 and is registered under company number 16998562. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is ADK CLINICAL DEVELOPMENT CONSULTANCY LTD?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of ADK CLINICAL DEVELOPMENT CONSULTANCY LTD?
ADK CLINICAL DEVELOPMENT CONSULTANCY LTD's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does ADK CLINICAL DEVELOPMENT CONSULTANCY LTD do?
ADK CLINICAL DEVELOPMENT CONSULTANCY LTD operates in the following sectors: 62020 - Information technology consultancy activities, 72190 - Other research and experimental development on natural sciences and engineering. These SIC codes provide insight into the company's business activities and industry focus.
What is ADK CLINICAL DEVELOPMENT CONSULTANCY LTD's registered address?
The registered office address of ADK CLINICAL DEVELOPMENT CONSULTANCY LTD is 4A ROYSTON ROAD, LITLINGTON, ROYSTON, ENGLAND, SG8 0RL. This is the official address filed with Companies House for legal and statutory correspondence.
Is ADK CLINICAL DEVELOPMENT CONSULTANCY LTD financially stable?
Financial accounts for ADK CLINICAL DEVELOPMENT CONSULTANCY LTD are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.